Affimed NV (Affimed NV) FCF Margin % : -6,288.89% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Affimed NV's Free Cash Flow for the three months ended in Dec. 2023 was $-28.30 Mil. Affimed NV's Revenue for the three months ended in Dec. 2023 was $0.45 Mil. Therefore, Affimed NV's FCF Margin % for the quarter that ended in Dec. 2023 was -6,288.89%.

As of today, Affimed NV's current FCF Yield % is -148.94%.

The historical rank and industry rank for Affimed NV's FCF Margin % or its related term are showing as below:

AFMD' s FCF Margin % Range Over the Past 10 Years
Min: -1384.4 Med: -252.06 Max: 205.26
Current: -1384.4

During the past 12 years, the highest FCF Margin % of Affimed NV was 205.26%. The lowest was -1384.40%. And the median was -252.06%.

AFMD's FCF Margin % is ranked worse than
79.07% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs AFMD: -1384.40

Affimed NV FCF Margin % Historical Data

The historical data trend for Affimed NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV FCF Margin % Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-142.72

-69.96

-224.05

-255.33

-1,377.63

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-281.08	-737.25	-2,398.01	-1,093.84	-6,288.89

Competitive Comparison of Affimed NV's FCF Margin %

For the Biotechnology subindustry, Affimed NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Affimed NV's FCF Margin % falls into.

Affimed NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Affimed NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-124.317	/	9.024
	=	-1,377.63 %

Affimed NV's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-28.3	/	0.45
	=	-6,288.89 %

Affimed NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Affimed NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.